Additional testing of PBI-05204 against patient derived tumors is being conducted at Rational Therapeutics (San Diego, CA).

The purpose of the research is to determine relative activity of PBI’s lead drug against pancreatic cancer for which very few active drugs exist. In addition, the relative activity of PBI-05204 in combination with standard of care cancer chemotherapeutic agents is also being examined. Initial results are encouraging.